BRAIN Biotech AG and Formo Bio GmbH launched a strategic collaboration to further advance the production of animal-free milk proteins. BRAIN Biotech is a leading industrial biotechnology company, Formo is a pioneering food-tech startup in the space of alternative milk protein. As experts in their field, the two German biotech companies are powering European innovation.
Using creativity and unconventional ideas, researchers and engineers at Evonik, one of the world leaders in specialty chemicals, have achieved a significant breakthrough in the biotechnological production of amino acids based on fermentation. They integrated the separating methods of chromatography and reverse osmosis and an online analytical method based on spectroscopy—all of which tend to be used in other industry sectors—in a biotechnological process. This created an outcome experts had previously considered nearly impossible. The researchers’ objective was to achieve optimal separation of the desired amino acid from a fermentation broth.
Evolva Holding SA has completed the placing of all shares earmarked to satisfy certain liabilities and transaction expenses related to the Allylix acquisition, a privately held yeast fermentation company with a focus on high-value ingredients, as announced on 16 December 2014. A total of 6.1 million shares were sold between 16 and 19 December. One Swiss investment fund acquired a block of five million shares. The transaction has no impact on the number of outstanding Evolva shares.
IL BIOECONOMISTA 